HOME >> BIOLOGY >> NEWS
Weizmann Institute scientists win global competition in predicting protein-protein interactions

Rehovot, Israel June 24, 2002-- A team of scientists from the Weizmann Institute of Science achieved the best result in the CAPRI (Critical Assessment of Prediction of Interactions) Challenge, an international competition in which participants submit predictions of structures of protein-protein complexes prior to experimental determination. The competitors were given three prediction targets, and sixteen teams from around the world submitted possible solutions. The Weizmann team, consisting of Dr. Miri Eisenstein of the Chemical Services Unit and her students Efrat Ben-Zeev, Alex Berchanski, Alex Heifetz and Boaz Shapira (also students of Prof. Ephraim Katzir in the Department of Biological Chemistry), was the only group to submit an acceptable prediction for each of the three targets. Dr. Eisenstein won a similar competition as part of a Weizmann Institute team six years ago.

Prediction of the structure of protein-protein complexes is an increasingly prominent field of endeavor in the current post-genome era, since new sequences and links between proteins are now regularly being discovered. "Docking" is a predictive method that uses computer algorithms to create three-dimensional models of the interactions formed between two protein molecules when they make contact, or "dock", with one another. The CAPRI Challenge, which requires that all competitors predict interactions for the same unbound molecules, provides a useful basis of comparison of different docking algorithms. The participants are given the structures of individual molecules and are requested to submit their predictions for the resulting complexes by a certain date, after which the experimental structures are made public. An independent group of assessors tests and compares all the predictions.

Predicting the ultimate complex structure of two unbound protein molecules is an exceptionally difficult task, since the proteins change their shapes in response to one another's presence
'"/>

Contact: Jeffrey J. Sussman
jeffrey@acwis.org
212-895-7951
American Committee for the Weizmann Institute of Science
24-Jun-2002


Page: 1 2

Related biology news :

1. Weizmann scientists invention moves forward: Cancer diagnosis technique gets FDA clearance
2. Psoriasis treatment based on Weizmann Institute Research passes phase II clinical trials
3. Weizmann Institute scientists report why taste and smell differ among individuals
4. Weizmann Institute scienists find that stem cells in the bone marrow become liver cells
5. Weizmann institute scientists solve the 3-D structure of the enzyme involved in Gaucher disease
6. Prize to Weizmann Institute professor for landmark work in stem cell transplantation
7. New witchweed-fighting method, presented by CIMMYT and Weizmann Institute scientist
8. Vaccination following spinal cord injury: Innovative Weizmann Institute approach limits paralysis
9. Weizmann Institute scientists block loss of eyesight in animals with a glaucoma-like disease
10. Weizmann Institute researcher named to Israel Academy Of Sciences And Humanities
11. Weizmann Institute scientists develop a novel system for analyzing genetic data that mimics the human capacity for unsupervised learning

Post Your Comments:
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: